Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TR-701 di-sodium phosphate salt
TR-701 di- salt · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| free acid | EXPERIMENTAL | TR-701 free acid phosphate powder in capsule formulation (equivalent to 150 mg TR-700) |
| di-sodium phosphate salt | EXPERIMENTAL | One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700) |
| Name | Type | Description |
|---|---|---|
| TR-701 di-sodium phosphate salt | DRUG | One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700) |
| TR-701 free acid phosphate | DRUG | One 182 mg capsule of TR-701 free acid phosphate (equivalent to 150 mg TR-700) |
Inclusion Criteria: * In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, and vital signs; * Females will be non-pregnant, non-lactating, and either postmenopausal for at least 1 year, surgically sterile for at least 90 days, or ...
TR-701 di- salt is an investigational small molecule developed by Merck & Company, Inc. (MRK). It is also known as TR-701 di-sodium phosphate salt. The compound has been studied in a Phase 1 clinical trial and is not approved for any indication.
TR-701 di- salt is being developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor of the clinical program for this investigational small molecule.
TR-701 di- salt is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA for any use.
TR-701 di- salt has been evaluated in one completed Phase 1 trial, NCT00876655, titled an Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate. The trial enrolled 12 healthy adult volunteers in the United States and was randomized and controlled.
Yes, TR-701 di- salt is also known as TR-701 di-sodium phosphate salt. Both names refer to the same investigational small molecule developed by Merck & Company, Inc. (MRK).